Multivalent BVDV-1b Vaccine Composition for Livestock Immunity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccines for Bovine Viral Diarrhea Virus (BVDV) are ineffective in preventing infections, particularly Type 1b subtype, leading to high mortality rates and economic losses in livestock due to antimicrobial resistance and lack of effective prophylaxis against multifactorial diseases like Bovine Respiratory Disease Complex (BRDC).
Innovation Solution
Development of immunogenic compositions containing modified, live BVDV-1b viruses and multivalent vaccine formulations that induce a vigorous immune response, including hexavalent vaccines targeting BVDV-1b, BVDV-1a, BVDV-2, BHV-1, PI 3, and BRSV, administered through various routes to elicit a protective immune response in livestock.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional BVDV vaccines are used, then vaccination coverage is achieved, but they are ineffective against BVDV-1b subtype leading to high mortality rates
Solution Approach 1:
The patent applies parameter changes by modifying the viral strain specificity from general BVDV types to specifically target BVDV-1b subtype. The vaccine composition uses modified live BVDV-1b viruses (including strains like TGAC, S1, and S2) which have been genetically characterized and selected for their efficacy against the predominant 1b subtype circulating in feedlots, thereby changing the protective parameter from general to subtype-specific immunity.
Solution Approach 2:
The patent segments the vaccine protection by providing separate coverage for different BVDV subtypes (1a, 1b, and 2) through multivalent formulations. This segmentation allows the vaccine to specifically address the 1b subtype problem while maintaining broader protection capabilities, with each viral strain in the composition targeting specific epitopes and immune responses.
2Reliability
If maternal antibodies are present in nursing calves, then passive immunity is provided, but they deplete injected immunogen and neutralize the vaccine
Solution Approach 1:
The patent applies preliminary action by timing the vaccination to occur after maternal antibody levels have naturally declined. The specification recommends vaccinating calves at specific ages (e.g., 6-12 months old) when maternal antibodies have waned sufficiently to allow the vaccine immunogen to remain in the system long enough to stimulate active immune response, thereby preemptively solving the neutralization problem through proper administration timing.
Solution Approach 2:
The patent applies dynamics by adjusting vaccination strategies based on the dynamic levels of maternal antibodies. The formulation and administration protocol account for the changing antibody titers over time, allowing the vaccine to be effective at specific developmental stages when the dynamic balance between maternal protection and vaccine responsiveness is optimal.
3Adaptability or versatility
If polyvalent vaccines are used for multifactorial diseases like BRDC, then broad coverage is attempted, but they are largely ineffective at preventing BVDV-1b infection
Solution Approach 1:
The patent segments the vaccine formulation into distinct viral components, with emphasis on including specific BVDV-1b strains (TGAC, S1, S2) as separate, well-defined immunogenic elements within the multivalent composition. This segmentation ensures that the critical 1b subtype protection is not diluted or compromised by other vaccine components, while still allowing for broader BRDC coverage through inclusion of other relevant pathogens.
Solution Approach 2:
The patent applies local quality by ensuring that specific regions or components of the vaccine formulation (the BVDV-1b viral strains) possess enhanced protective properties tailored to the specific threat of 1b subtype. The formulation gives specialized attention to including strains with proven efficacy against 1b, while other components address different pathogens, allowing each part to have optimized quality for its specific function.
Data Source
AI summary
Disclosed are immunogenic compositions comprising a modified, live bovine viral diarrhea virus type lb (BVDV-lb), and methods for their use in the formulation and administration of therapeutic and prophylactic pharmaceutical agents. In particular, the invention provides immunogenic compositions and methods for preventing, treating, managing, and/or ameliorating a viral or microbial infection, or one or more symptoms thereof, including, for example, those infections giving rise to shipping fever, bovine respiratory disease complex, and/or bovine viral diarrhea, particularly in susceptible or infected animals.